The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

ACY-241, a histone deacetylase 6 inhibitor, suppresses the epithelial-mesenchymal transition in lung cancer cells by downregulating hypoxia-inducible factor-1 alpha

  • Received : 2023.10.30
  • Accepted : 2023.11.27
  • Published : 2024.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Hypoxia-inducible factor-1 alpha (HIF-1α) is a transcription factor activated under hypoxic conditions, and it plays a crucial role in cellular stress regulation. While HIF-1α activity is essential in normal tissues, its presence in the tumor microenvironment represents a significant risk factor as it can induce angiogenesis and confer resistance to anti-cancer drugs, thereby contributing to poor prognoses. Typically, HIF-1α undergoes rapid degradation in normoxic conditions via oxygen-dependent degradation mechanisms. However, certain cancer cells can express HIF-1α even under normoxia. In this study, we observed an inclination toward increased normoxic HIF-1α expression in cancer cell lines exhibiting increased HDAC6 expression, which prompted the hypothesis that HDAC6 may modulate HIF-1α stability in normoxic conditions. To prove this hypothesis, several cancer cells with relatively higher HIF-1α levels under normoxic conditions were treated with ACY-241, a selective HDAC6 inhibitor, and small interfering RNAs for HDAC6 knockdown. Our data revealed a significant reduction in HIF-1α expression upon HDAC6 inhibition. Moreover, the downregulation of HIF-1α under normoxic conditions decreased zinc finger E-box-binding homeobox 1 expression and increased E-cadherin levels in lung cancer H1975 cells, consequently suppressing cell invasion and migration. ACY-241 treatment also demonstrated an inhibitory effect on cell invasion and migration by reducing HIF-1α level. This study confirms that HDAC6 knockdown and ACY-241 treatment effectively decrease HIF-1α expression under normoxia, thereby suppressing the epithelial-mesenchymal transition. These findings highlight the potential of selective HDAC6 inhibition as an innovative therapeutic strategy for lung cancer.

Keywords

Acknowledgement

This research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2016R1A6A1A03011325) and Ministry of Science and ICT (MSIT) (No. NRF-2022R1A2C1008787).

References

  1. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535-554. https://doi.org/10.1016/S0140-6736(21)00312-3
  2. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012;7:924-933. https://doi.org/10.1097/JTO.0b013e31824cc334
  3. Dong J, Li B, Lin D, Zhou Q, Huang D. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 2019;10:230.
  4. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781-783. https://doi.org/10.1101/gad.1787609
  5. Luo J, Huang Z, Wei W, Sun Y, Gong Y. Editorial: epigenetic regulation and non-histone post-translational modification in cancer. Front Genet. 2023;14:1176174.
  6. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4:5.
  7. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011;2011:875824.
  8. Wang Z, Tang F, Hu P, Wang Y, Gong J, Sun S, Xie C. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep. 2016;36:589-597. https://doi.org/10.3892/or.2016.4811
  9. Pulya S, Amin SA, Adhikari N, Biswas S, Jha T, Ghosh B. HDAC6 as privileged target in drug discovery: a perspective. Pharmacol Res. 2021;163:105274.
  10. Dong J, Zheng N, Wang X, Tang C, Yan P, Zhou HB, Huang J. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer. Eur J Pharmacol. 2018;828:67-79. https://doi.org/10.1016/j.ejphar.2018.03.026
  11. Li J, Yu M, Fu S, Liu D, Tan Y. Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front Pharmacol. 2022;13:907981. Erratum in: Front Pharmacol. 2022;13:1117936.
  12. Park SJ, Joo SH, Lee N, Jang WJ, Seo JH, Jeong CH. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Arch Pharm Res. 2021;44:1062-1075. https://doi.org/10.1007/s12272-021-01359-x
  13. Zhang XH, Kang HQ, Tao YY, Li YH, Zhao JR, Ya-Gao, Ma LY, Liu HM. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. Eur J Med Chem. 2021;218:113392.
  14. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle. 2008;7:2090-2096. https://doi.org/10.4161/cc.7.14.6324
  15. Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-inducible factors and cancer. Curr Sleep Med Rep. 2017;3:1-10. https://doi.org/10.1007/s40675-017-0062-7
  16. Kurtipek E, Kocak N, Esme H, Duzgun N, Akin SE, unlu Y, Bekci TT. The role of HIF-1 pathway in non-small-cell lung cancer. Eur Respir J.2016;48:PA2855.
  17. Zhu J, Huang Z, Zhang M, Wang W, Liang H, Zeng J, Wu K, Wang X, Hsieh JT, Guo P, Fan J. HIF-1α promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model. Oncol Lett. 2018;15:3482-3489. Erratum in: Oncol Lett. 2021;22:599.
  18. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445-2453. https://doi.org/10.1096/fj.01-0125com
  19. Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CY, Hanna G, Rich JN, Provenzale JM, Dewhirst MW. Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res. 2013;73:6230-6242. https://doi.org/10.1158/0008-5472.CAN-12-1345
  20. Ryu HW, Won HR, Lee DH, Kwon SH. HDAC6 regulates sensitivity to cell death in response to stress and post-stress recovery. Cell Stress Chaperones. 2017;22:253-261. https://doi.org/10.1007/s12192-017-0763-3
  21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. https://doi.org/10.1006/meth.2001.1262
  22. Zhang Q, Zhang ZF, Rao JY, Sato JD, Brown J, Messadi DV, Le AD. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer. 2004;111:849-857. https://doi.org/10.1002/ijc.20334
  23. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378-389. https://doi.org/10.1016/j.apsb.2015.05.007
  24. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, Engel P, Postigo A. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010;29:3490-3500. https://doi.org/10.1038/onc.2010.102
  25. Haase VH. The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des. 2009;15:3895-3903. https://doi.org/10.2174/138161209789649394
  26. Li T, Mao C, Wang X, Shi Y, Tao Y. Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation. J Exp Clin Cancer Res. 2020;39:224.
  27. Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle. 2006;5:2430-2435. https://doi.org/10.4161/cc.5.21.3409
  28. Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 2006;25:1231-1241. https://doi.org/10.1038/sj.emboj.7601025
  29. Seo HW, Kim EJ, Na H, Lee MO. Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1. FEBS Lett. 2009;583:55-60. https://doi.org/10.1016/j.febslet.2008.11.044
  30. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006;26:2019-2028. https://doi.org/10.1128/MCB.26.6.2019-2028.2006
  31. Geng H, Liu Q, Xue C, David LL, Beer TM, Thomas GV, Dai MS, Qian DZ. HIF1α protein stability is increased by acetylation at lysine 709. J Biol Chem. 2012;287:35496-35505. https://doi.org/10.1074/jbc.M112.400697
  32. Saito S, Zhuang Y, Shan B, Danchuk S, Luo F, Korfei M, Guenther A, Lasky JA. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway. PLoS One. 2017;12:e0186615.
  33. Schoepflin ZR, Shapiro IM, Risbud MV. Class I and IIa HDACs mediate HIF-1α stability through PHD2-dependent mechanism, while HDAC6, a Class IIb member, promotes HIF-1α transcriptional activity in nucleus pulposus cells of the intervertebral disc. J Bone Miner Res. 2016;31:1287-1299. https://doi.org/10.1002/jbmr.2787
  34. McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. Prostate. 2018;78:266-277. https://doi.org/10.1002/pros.23467
  35. Yang L, Chang Y, Cao P. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells. Exp Cell Res. 2018;371:231-237. https://doi.org/10.1016/j.yexcr.2018.08.015
  36. Wang J, Xu MQ, Jiang XL, Mei XY, Liu XG. Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells. Anticancer Drugs. 2018;29:80-88. https://doi.org/10.1097/CAD.0000000000000573
  37. Wawruszak A, Kalafut J, Okon E, Czapinski J, Halasa M, Przybyszewska A, Miziak P, Okla K, Rivero-Muller A, Stepulak A. Histone deacetylase inhibitors and phenotypical transformation of cancer cells. Cancers (Basel). 2019;11:148.